Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Osteoarthritis: Role of Peroxisome Proliferator-Activated Receptors.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- المؤلفون: Sheng, Weibei1,2 (AUTHOR); Wang, Qichang1,2 (AUTHOR); Qin, Haotian1,2 (AUTHOR); Cao, Siyang1,2 (AUTHOR); Wei, Yihao1,2 (AUTHOR); Weng, Jian1,2 (AUTHOR); Yu, Fei1,2 (AUTHOR) ; Zeng, Hui1,2 (AUTHOR)
- المصدر:
International Journal of Molecular Sciences. Sep2023, Vol. 24 Issue 17, p13137. 17p.
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
Osteoarthritis (OA) represents the foremost degenerative joint disease observed in a clinical context. The escalating issue of population aging significantly exacerbates the prevalence of OA, thereby imposing an immense annual economic burden on societies worldwide. The current therapeutic landscape falls short in offering reliable pharmaceutical interventions and efficient treatment methodologies to tackle this growing problem. However, the scientific community continues to dedicate significant efforts towards advancing OA treatment research. Contemporary studies have discovered that the progression of OA may be slowed through the strategic influence on peroxisome proliferator-activated receptors (PPARs). PPARs are ligand-activated receptors within the nuclear hormone receptor family. The three distinctive subtypes—PPARα, PPARβ/δ, and PPARγ—find expression across a broad range of cellular terminals, thus managing a multitude of intracellular metabolic operations. The activation of PPARγ and PPARα has been shown to efficaciously modulate the NF-κB signaling pathway, AP-1, and other oxidative stress-responsive signaling conduits, leading to the inhibition of inflammatory responses. Furthermore, the activation of PPARγ and PPARα may confer protection to chondrocytes by exerting control over its autophagic behavior. In summation, both PPARγ and PPARα have emerged as promising potential targets for the development of effective OA treatments. [ABSTRACT FROM AUTHOR]
No Comments.